SEQUENCE LISTING

<110> Rondon, Isaac J
Ladner, Robert C

<120> BINDING PEPTIDES FOR CARCINOEMBRYONIC ANTIGEN (CEA)

<130> Sequence Listing DYX-016.1 US

<140> (not yet assigned)
<141> 2001-04-03

<150> US 09/541345
<151> 2000-04-03

<160> 151

<170> PatentIn Ver. 2.1

<210> 1
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<220>
<221> VARIANT
<222> (1)
<223> Xaa is Asn, Asp or is absent

<220>
<221> VARIANT
<222> (2)
<223> Xaa is Trp

<220>
<221> VARIANT
<222> (3)
<223> Xaa is Asp, Phe or Val

<220>
<221> VARIANT
<222> (5)
<223> Xaa is Asn, Glu or Met

<220>
<221> VARIANT
<222> (6)
<223> Xaa is Asn, Leu, Met or Phe

<220>
<221> VARIANT
<222> (7)
<223> Xaa is Asp, Gly, Ile, Lys, Phe or Thr

<220>
<221> VARIANT
<222> (8)
<223> Xaa is Ala, Gln, gly Lys or Thr

<220>
<221> VARIANT
<222> (9)
<223> Xaa is Arg, Asn, Asp, Glu or Gly

<220>
<221> VARIANT
<222> (10)
<223> Xaa is Gln, Leu or Gly

<220>
<221> VARIANT
<222> (11)
<223> Xaa is Ala, Trp or Tyr

<220>
<221> VARIANT
<222> (12)
<223> Xaa is Ala, Gly, His, Phe, Thr or Val

<220>
<221> VARIANT
<222> (14)
<223> Xaa is Asn, Gln, Phe, Ser or Val

<220>
<221> VARIANT
<222> (15)
<223> Xaa is Arg, Leu Pro or Ser

<220>
<221> VARIANT
<222> (16)

<223> Xaa is Leu, Ser, Trp or Tyr

<400> 1
Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15

<210> 2
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: family of preferred CEA binding moieties

<220>
<221> VARIANT
<222> (1)
<223> Xaa is Asn or Asp

<220>
<221> VARIANT
<222> (6)
<223> Xaa is Ph, Met, Leu or Asn

<220>
<221> VARIANT
<222> (7)
<223> Xaa is Asp, Gly, Ile, Lys, Phe or Thr

<220>
<221> VARIANT
<222> (9)
<223> Xaa is Arg, Asn, Asp, Glu, Gly or Trp

<220>
<221> VARIANT
<222> (12)
<223> Xaa is Ala, Gly, His, Phe, Thr, Tyr or Val

<220>
<221> VARIANT
<222> (15)
<223> Xaa is Arg, Leu, Pro or Ser

<220>
<221> VARIANT

<222> (16)
<223> Xaa is Leu, Ser, Trp or Tyr

<400> 2
Xaa Trp Val Cys Glu Xaa Xaa Lys Xaa Gln Trp Xaa Cys Asn Xaa Xaa
1 5 10 15

<210> 3
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding loop

<220>
<221> VARIANT
<222> (2)
<223> Xaa is Asn, Glu or Met

<220>
<221> VARIANT
<222> (3)
<223> Xaa is Asn, Leu, Net or Phe

<220>
<221> VARIANT
<222> (4)
<223> Xaa is Asp, Gly, Ile, Lys, Phe or Thr

<220>
<221> VARIANT
<222> (5)
<223> Xaa is Ala, Gln, Gly, Lys or Thr

<220>
<221> VARIANT
<222> (6)
<223> Xaa is Arg, Asn, Asp, Glu or Gly

<220>
<221> VARIANT
<222> (7)
<223> Xaa is Gln, Gly or Leu

<220>

<221> VARIANT
<222> (8)
<223> Xaa is Ala, Trp or Tyr

<220>
<221> VARIANT
<222> (9)
<223> Xaa is Ala, Gly, His, Phe, Thr or Val

<400> 3
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
1 5 10

<210> 4
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 4
Asn Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asn Ser Tyr
1 5 10 15

<210> 5
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 5
Asp Trp Val Cys Glu Asn Lys Lys Asp Gln Trp Thr Cys Asn Leu Leu
1 5 10 15

<210> 6
<211> 16
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 6
Asn Trp Asp Cys Met Phe Gly Ala Glu Gly Trp Ala Cys Ser Pro Trp
1 5 10 15

<210> 7
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 7
Asp Trp Val Cys Glu Lys Thr Thr Gly Gly Tyr Val Cys Gln Pro Leu
1 5 10 15

<210> 8
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 8
Asn Trp Phe Cys Glu Met Ile Gly Arg Gln Trp Gly Cys Val Pro Ser
1 5 10 15

<210> 9
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 9
Asp Trp Val Cys Asn Phe Asp Gln Gly Leu Ala His Cys Phe Pro Ser
1 5 10 15

<210> 10
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: parental
domain for design of microprotein display library

<220>
<221> VARIANT
<222> (1)..(12)
<223> amino acid positions 4 and 9 are invariant Cys;
all other positions Xaa are varied but not Cys, to
provide a library of 2x10(8) different peptides
based on the template sequence

<400> 10
Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5 10

<210> 11
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: parental
domain for design of microprotein display library

<220>
<221> VARIANT
<222> (1)..(11)
<223> amino acid positions 3 and 9 are invariant Cys;
all other positions Xaa are varied but not Cys, to
provide a library of 1x10(9) different peptides
based on the template sequence

<400> 11
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa
1 5 10

<210> 12
<211> 12

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: parental
domain for design of microprotein display library

<220>
<221> VARIANT
<222> (1)..(12)
<223> amino acid positions 3 and 10 are invariant Cys;
all other positions Xaa are varied but not Cys, to
provide a library of 1x10(9) different peptides
based on the template sequence

<400> 12
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa
1 5 10

<210> 13
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: parental
domain for design of microprotein display library

<220>
<221> VARIANT
<222> (1)..(16)
<223> amino acid positions 4 and 13 are invariant Cys;
all other positions Xaa are varied but not Cys, to
provide a library of 2.5x10(8) different peptides
based on the template sequence

<400> 13
Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15

<210> 14
<211> 16
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: variable
sublibrary sequence used in designing focused
secondary library

<220>
<221> VARIANT
<222> (1)..(3)
<223> Xaa is any amino acid except Cys

<220>
<221> VARIANT
<222> (5)..(6)
<223> Xaa is any amino acid except Cys

<400> 14
Xaa Xaa Xaa Cys Xaa Xaa Lys Lys Asp Gln Trp Thr Cys Asn Leu Leu
1 5 10 15

<210> 15
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: variable
sublibrary sequence used in designing focused
secondary library

<220>
<221> VARIANT
<222> (5)..(9)
<223> Xaa is any amino acid except Cys

<400> 15
Asp Trp Val Cys Xaa Xaa Xaa Xaa Xaa Gln Trp Thr Cys Asn Leu Leu
1 5 10 15

<210> 16
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: variable
sublibrary sequence used in designing focused
secondary library

<220>
<221> VARIANT
<222> (8)..(12)
<223> Xaa is any amino acid except Cys

<400> 16
Asp Trp Val Cys Glu Asn Lys Xaa Xaa Xaa Xaa Xaa Cys Asn Leu Leu
1 5 10 15

<210> 17
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: variable sublibrary sequence used in designing focused secondary library

<220>
<221> VARIANT
<222> (11)..(12)
<223> Xaa is any amino acid except Cys

<220>
<221> VARIANT
<222> (14)..(16)
<223> Xaa is any amino acid except Cys

<400> 17
Asp Trp Val Cys Glu Asn Lys Lys Asp Gln Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15

<210> 18
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: variable sublibrary sequence used in designing focused secondary library

<220>
<221> VARIANT

<222> (6)..(7)
<223> Xaa is any amino acid except Cys

<220>
<221> VARIANT
<222> (9)
<223> Xaa is any amino acid except Cys

<220>
<221> VARIANT
<222> (12)
<223> Xaa is any amino acid except Cys

<220>
<221> VARIANT
<222> (15)
<223> Xaa is any amino acid except Cys

<400> 18
Asp Trp Val Cys Glu Xaa Xaa Lys Xaa Gln Trp Xaa Cys Asn Xaa Leu
1 5 10 15

<210> 19
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: variable sublibrary sequence used in designing focused secondary library

<220>
<221> VARIANT
<222> (5)..(7)
<223> Xaa is any amino acid except Cys

<220>
<221> VARIANT
<222> (9)
<223> Xaa is any amino acid except Cys

<220>
<221> VARIANT
<222> (12)
<223> Xaa is any amino acid except Cys

<400> 19
Asn Trp Val Cys Xaa Xaa Xaa Lys Xaa Gln Trp Xaa Cys Asn Ser Tyr
1 5 10 15

<210> 20
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: variable sublibrary sequence used in designing focused secondary library

<220>
<221> VARIANT
<222> (1)
<223> Xaa is any amino acid except Cys

<220>
<221> VARIANT
<222> (3)
<223> Xaa is any amino acid except Cys

<220>
<221> VARIANT
<222> (14)..(16)
<223> Xaa is any amino acid except Cys

<400> 20
Xaa Trp Xaa Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Xaa Xaa Xaa
1 5 10 15

<210> 21
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: isolate of TN10/9 library found not to bind CEA

<400> 21
Asn Trp Arg Cys Lys Leu Phe Pro Arg Tyr Pro Tyr Cys Ser Ser Trp
1 5 10 15

<210> 22
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: isolate of
TN10/9 library found not to bind CEA

<400> 22
Arg Tyr Cys Glu Phe Phe Pro Trp Ser Leu His Cys Gly Arg Pro
1 5 10 15

<210> 23
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: conserved
amino acid positions in first family of CEA
binding peptides

<220>
<221> VARIANT
<222> (6)
<223> X is Asn, Leu, Met or Phe

<220>
<221> VARIANT
<222> (7)
<223> X is Asp, Gly, Ile, Lys, Phe or Thr

<220>
<221> VARIANT
<222> (9)
<223> X is Arg, Asn, Asp, Glu or Gly

<220>
<221> VARIANT
<222> (12)
<223> X is Ala, Gly, His, Phe, Thr or Val

<220>
<221> VARIANT
<222> (15)

<223> X is Arg, Leu, Pro or Ser

<400> 23
Asp Trp Val Cys Glu Xaa Xaa Lys Xaa Gln Trp Xaa Cys Asn Xaa Leu
1 5 10 15

<210> 24
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic CEA binding peptide with C-terminal immobilization sequence

<400> 24
Ser Asn Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asn Ser
1 5 10 15

Tyr Ala Pro Gly Gly Glu Gly Gly Gly Ser Lys
20 25

<210> 25
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic CEA binding peptide with C-terminal immobilization sequence

<400> 25
Ser Asp Trp Val Cys Glu Asn Lys Lys Asp Gln Trp Thr Cys Asn Leu
1 5 10 15

Leu Ala Pro Gly Gly Glu Gly Gly Gly Ser Lys
20 25

<210> 26
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic CEA binding peptide with C-terminal immobilization sequence

<400> 26
Ser Asn Trp Asp Cys Met Phe Gly Ala Glu Gly Trp Ala Cys Ser Pro
1 5 10 15

Trp Ala Pro Gly Gly Glu Gly Gly Gly Ser Lys
20 25

<210> 27
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic CEA binding peptide with C-terminal immobilization sequence

<400> 27
Ser Asp Trp Val Cys Glu Leu Thr Thr Gly Gly Tyr Val Cys Gln Pro
1 5 10 15

Leu Ala Pro Gly Gly Glu Gly Gly Gly Ser Lys
20 25

<210> 28
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: C-terminal sequence for immobilizing peptides

<400> 28
Ala Pro Gly Gly Glu Gly Gly Gly Ser Lys
1 5 10

<210> 29
<211> 16
<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: template
sequence for sublibrary used in construction of
focused secondary display library

<220>
<221> VARIANT
<222> (1)..(3)
<223> X is any amino acid except Cys

<220>
<221> VARIANT
<222> (5)..(6)
<223> X is any amino acid except Cys

<400> 29
Xaa Xaa Xaa Cys Xaa Xaa Lys Lys Asp Gln Trp Thr Cys Asn Leu Leu
1 5 10 15

<210> 30
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: template
sequence for sublibrary used in construction of
focused secondary display library

<220>
<221> VARIANT
<222> (5)..(9)
<223> X is any amino acid except Cys

<400> 30
Asp Trp Val Cys Xaa Xaa Xaa Xaa Xaa Gln Trp Thr Cys Asn Leu Leu
1 5 10 15

<210> 31
<211> 16
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: template
sequence for sublibrary used in construction of
focused secondary display library

<220>
<221> VARIANT
<222> (8)..(12)
<223> X is any amino acid except Cys

<400> 31
Asp Trp Val Cys Glu Asn Lys Xaa Xaa Xaa Xaa Xaa Cys Asn Leu Leu
1 5 10 15

<210> 32
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: template
sequence for sublibrary used in construction of
focused secondary display library

<220>
<221> VARIANT
<222> (11)..(12)
<223> X is any amino acid except Cys

<220>
<221> VARIANT
<222> (14)..(16)
<223> X is any amino acid except Cys

<400> 32
Asp Trp Val Cys Glu Asn Lys Lys Asp Gln Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15

<210> 33
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: template
sequence for sublibrary used in construction of
focused secondary display library

<220>
<221> VARIANT
<222> (6)..(7)
<223> X is any amino acid except Cys

<220>
<221> VARIANT
<222> (9)
<223> X is any amino acid except Cys

<220>
<221> VARIANT
<222> (12)
<223> X is any amino acid except Cys

<220>
<221> VARIANT
<222> (15)
<223> X is any amino acid except Cys

<400> 33
Asp Trp Val Cys Glu Xaa Xaa Lys Xaa Gln Trp Xaa Cys Asn Xaa Leu
1 5 10 15

<210> 34
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: template sequence for sublibrary used in construction of focused secondary display library

<220>
<221> VARIANT
<222> (5)..(7)
<223> X is any amino acid except Cys

<220>
<221> VARIANT
<222> (9)
<223> X is any amino acid except Cys

<220>
<221> VARIANT

<222> (12)
<223> X is any amino acid except Cys

<400> 34
Asn Trp Val Cys Xaa Xaa Xaa Lys Xaa Gln Trp Xaa Cys Asn Ser Tyr
1 5 10 15

<210> 35
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: template sequence for sublibrary used in construction of focused secondary display library

<220>
<221> VARIANT
<222> (1)
<223> X is any amino acid except Cys

<220>
<221> VARIANT
<222> (3)
<223> X is any amino acid except Cys

<220>
<221> VARIANT
<222> (14)..(16)
<223> X is any amino acid except Cys

<400> 35
Xaa Trp Xaa Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Xaa Xaa Xaa
1 5 10 15

<210> 36
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: family of CEA binding polypeptides

<220>

<221> VARIANT
<222> (1)
<223> Xaa is Asp, Asn, Ala or Ile

<220>
<221> VARIANT
<222> (3)
<223> Xaa is Val, Ile, Met, Tyr, Phe, Pro or Asp

<220>
<221> VARIANT
<222> (5)
<223> Xaa is Asn, Glu or Asp

<220>
<221> VARIANT
<222> (6)
<223> Xaa is Leu, Phe, Typ, Trp, Val Met, Ile or Asn

<220>
<221> VARIANT
<222> (7)
<223> Xaa is Phe, Leu, Asp, Glu, Ala, Ile, Lys, Asn,
Ser, Val, Trp or Tyr

<220>
<221> VARIANT
<222> (8)
<223> Xaa is Lys, Phe, Asp, Gly, Leu, Asn or Trp

<220>
<221> VARIANT
<222> (9)
<223> Xaa is Asn, Pro, Phe, Gly, Asp, Ala, Ser, Glu, Gln
or Trp

<220>
<221> VARIANT
<222> (10)
<223> Xaa is Gln or Lys

<220>
<221> VARIANT
<222> (12)
<223> Xaa is Phe, Thr, Met, Ser, Ala, Asn, Val, His,
Ile, Pro, Trp or Tyr

<220>

<221> VARIANT
<222> (14)
<223> Xaa is Asn, Asp, Glu, Pro, Gln or Ser

<220>
<221> VARIANT
<222> (15)
<223> Xaa is Val, Leu, Ile, Pro, Ala, Gln, Ser, Met,
Glu,Thr, Lys or Trp

<220>
<221> VARIANT
<222> (16)
<223> Xaa is Leu, Met, Val, Tyr, Ala, Ile, Trp, His,
Pro, Gln, Glu, Phe, Lys or Arg

<400> 36
Xaa Trp Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Trp Xaa Cys Xaa Xaa Xaa
1 5 10 15

<210> 37
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 37
Asp Trp Met Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Leu Met
1 5 10 15

<210> 38
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 38
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Leu Met
1 5 10 15

<210> 39
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 39
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Gln Met
1 5 10 15

<210> 40
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 40
Asn Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Gln Glu
1 5 10 15

<210> 41
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 41
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Gln Val Lys
1 5 10 15

<210> 42
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 42
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Val Met
1 5 10 15

<210> 43
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 43
Asp Trp Met Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Gln Ile
1 5 10 15

<210> 44
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 44
Ile Trp Asp Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Pro Ala Pro
1 5 10 15

<210> 45
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 45
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Ile Arg

1 5 10 15

<210> 46
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 46
Asp Trp Met Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Val Val
1 5 10 15

<210> 47
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 47
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Ala Ile
1 5 10 15

<210> 48
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 48
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Met Ala
1 5 10 15

<210> 49
<211> 16
<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 49
Asp Trp Val Cys Glu Phe Leu Lys Met Gln Trp Ala Cys Asn Val Leu
1 5 10 15

<210> 50
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 50
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asn Val Met
1 5 10 15

<210> 51
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 51
Ala Trp Pro Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Pro Pro Gln
1 5 10 15

<210> 52
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 52
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Val Leu
1 5 10 15

<210> 53
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 53
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Lys Trp
1 5 10 15

<210> 54
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 54
Asp Trp Val Cys Glu Trp Leu Lys Met Gln Trp Ala Cys Asn Met Leu
1 5 10 15

<210> 55
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 55
Asp Trp Val Cys Asp Phe Phe Phe Asn Gln Trp Thr Cys Asn Leu Leu
1 5 10 15

<210> 56

<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 56
Asp Trp Val Cys Glu Met Phe Lys Ala Gln Trp Phe Cys Asn Ala Leu
1 5 10 15

<210> 57
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 57
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Ala Trp
1 5 10 15

<210> 58
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 58
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Val Trp
1 5 10 15

<210> 59
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding

polypeptide

<400> 59
Asp Trp Val Cys Glu Tyr Phe Lys Asn Gln Trp Phe Cys Asn Val Leu
1 5 10 15

<210> 60
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 60
Asp Trp Val Cys Glu Ile Asp Lys Gly Gln Trp Thr Cys Asn Pro Leu
1 5 10 15

<210> 61
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 61
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asn Pro Phe
1 5 10 15

<210> 62
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 62
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Val Gln
1 5 10 15

<210> 63
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 63
Asp Trp Val Cys Asn Leu Phe Phe Gly Gln Trp Thr Cys Asn Leu Leu
1 5 10 15

<210> 64
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 64
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Glu Ala His
1 5 10 15

<210> 65
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 65
Asp Trp Val Cys Glu Leu Val Lys Ala Gln Trp Tyr Cys Asn Ile Leu
1 5 10 15

<210> 66
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 66
Asn Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Thr Val
1 5 10 15

<210> 67
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 67
Asp Trp Val Cys Glu Phe Tyr Lys Ser Gln Trp Asn Cys Asn Ile Leu
1 5 10 15

<210> 68
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 68
Asp Trp Val Cys Glu Trp Phe Lys Pro Gln Trp Phe Cys Asn Pro Leu
1 5 10 15

<210> 69
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 69
Asp Trp Tyr Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Val Leu

1 5 10 15

<210> 70
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 70
Asp Trp Val Cys Glu Tyr Asn Asp Glu Gln Trp Thr Cys Asn Leu Leu
1 5 10 15

<210> 71
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 71
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asn Glu Ala
1 5 10 15

<210> 72
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 72
Asp Trp Val Cys Asn Trp Glu Leu Phe Gln Trp Thr Cys Asn Leu Leu
1 5 10 15

<210> 73
<211> 16
<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 73
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Gln Val
1 5 10 15

<210> 74
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 74
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Val Pro
1 5 10 15

<210> 75
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 75
Asp Trp Val Cys Glu Phe Phe Lys Gln Gln Trp Phe Cys Asn Val Leu
1 5 10 15

<210> 76
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 76
Asp Trp Val Cys Glu Phe Phe Lys Asp Gln Trp Ser Cys Asn Val Leu
1 5 10 15

<210> 77
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 77
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Ser Leu
1 5 10 15

<210> 78
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 78
Asp Trp Val Cys Glu Phe Met Lys His Gln Trp Phe Cys Asn Pro Leu
1 5 10 15

<210> 79
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 79
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Gln Ala Val
1 5 10 15

<210> 80

<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 80
Asp Trp Val Cys Glu Phe Ile Lys Asn Gln Trp Met Cys Asn Val Leu
1 5 10 15

<210> 81
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 81
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Ala Leu
1 5 10 15

<210> 82
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 82
Asp Trp Val Cys Glu Tyr Glu Lys Asp Gln Trp Ser Cys Asn Ile Leu
1 5 10 15

<210> 83
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding

polypeptide

<400> 83
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Thr Leu
1 5 10 15

<210> 84
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 84
Asp Trp Tyr Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Val Tyr
1 5 10 15

<210> 85
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 85
Asp Trp Phe Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Ser Pro Ile
1 5 10 15

<210> 86
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 86
Asp Trp Val Cys Glu Phe Phe Lys Lys Gln Trp Phe Cys Asn Leu Leu
1 5 10 15

<210> 87
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 87
Asn Trp Val Cys Asp Val Leu Lys Trp Gln Trp Pro Cys Asn Ser Tyr
1 5 10 15

<210> 88
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 88
Asp Trp Val Cys Glu Tyr Asp Lys Gly Gln Trp His Cys Asn Ile Leu
1 5 10 15

<210> 89
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 89
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Gln Gln His
1 5 10 15

<210> 90
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 90
Asp Trp Val Cys Asn Trp Leu Trp Gly Gln Trp Thr Cys Asn Leu Leu
1 5 10 15

<210> 91
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 91
Asp Trp Val Cys Glu Met Phe Lys Lys Gln Trp Val Cys Asn Pro Leu
1 5 10 15

<210> 92
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 92
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Gly Pro Leu
1 5 10 15

<210> 93
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 93
Asp Trp Val Cys Glu Val Ile Lys Asp Gln Trp Val Cys Asn Pro Leu

1 5 10 15

<210> 94
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 94
Asp Trp Val Cys Glu Asn Lys Asn Phe Lys Trp Phe Cys Asn Leu Leu
1 5 10 15

<210> 95
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 95
Asp Trp Val Cys Glu Tyr Ala Lys Asn Gln Trp Asn Cys Asn Pro Leu
1 5 10 15

<210> 96
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 96
Asn Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Glu Trp Ala
1 5 10 15

<210> 97
<211> 16
<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 97
Asn Trp Val Cys Asp Tyr Trp Lys Pro Gln Trp Phe Cys Asn Ser Tyr
1 5 10 15

<210> 98
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 98
Asp Trp Tyr Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Leu Val
1 5 10 15

<210> 99
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 99
Asn Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Glu Met
1 5 10 15

<210> 100
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 100
Asp Trp Val Cys Glu Leu Phe Lys Pro Gln Trp Phe Cys Asn Ile Leu
1 5 10 15

<210> 101
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 101
Asp Trp Val Cys Glu Trp Ser Lys Met Gln Trp Ser Cys Asn Ala Leu
1 5 10 15

<210> 102
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 102
Asp Trp Val Cys Asp Tyr Lys Phe Phe Gln Trp Thr Cys Asn Leu Leu
1 5 10 15

<210> 103
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding polypeptide

<400> 103
Asn Trp Val Cys Glu Trp Leu Lys Pro Gln Trp Trp Cys Asn Ser Tyr
1 5 10 15

<210> 104

<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 104
Asp Trp Val Cys Glu Phe Phe Lys Pro Gln Trp Met Cys Asn Ile Leu
1 5 10 15

<210> 105
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 105
Asp Trp Val Cys Glu Tyr Phe Lys Ser Gln Trp Met Cys Asn Met Leu
1 5 10 15

<210> 106
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding
polypeptide

<400> 106
Asp Trp Val Cys Glu Phe Phe Gly Met Gln Trp Thr Cys Asn Leu Leu
1 5 10 15

<210> 107
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CEA binding

polypeptide

<400> 107
Asp Trp Val Cys Glu Tyr Ala Lys Phe Gln Trp Ile Cys Asn Ile Leu
1 5 10 15

<210> 108
<211> 16
<212> PRT
<213> Artificial Sequence

<400> 108
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asn Glu Ala
1 5 10 15

<210> 109
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 109
Asp Trp Val Cys Glu Tyr Phe Lys Asn Gln Trp Phe Cys Asp Thr Leu
1 5 10 15

<210> 110
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<220>
<221> VARIANT
<222> (2)
<223> X is Asn, Glu, Asp or Met

<220>
<221> VARIANT
<222> (3)

<223> X is Leu, Phe, Tyr, Trp, Val, Met, Ile or Asn

<220>
<221> VARIANT
<222> (4)
<223> X is Phe, Leu, Asp, Glu, Ala, Ile, Lys, Asn, Ser, Val, Trp, Tyr, Gly or Thr

<220>
<221> VARIANT
<222> (5)
<223> X is Lys, Phe, Asp, Gly, Leu, Asn, Trp, Ala, Gln or Thr

<220>
<221> VARIANT
<222> (6)
<223> X is Asn, Pro, Phe, Gly, Asp, Ala, Ser, Glu, Gln, Trp, His, Arg, Met, Val or Leu

<220>
<221> VARIANT
<222> (7)
<223> X is Gln, Lys, Leu or Gly

<220>
<221> VARIANT
<222> (8)
<223> X is Tyr, Trp or Ala

<220>
<221> VARIANT
<222> (9)
<223> X is Phe, Thr, Met, Ser, Ala, Asn, Val, His, Ile, Pro, Trp, Tyr, Gly, Leu or Glu

<400> 110
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
1 5 10

<210> 111
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic

16-mer microprotein analogues

<220>
<221> VARIANT
<222> (1)
<223> X is Asp, Asn, Ala or Ile

<220>
<221> VARIANT
<222> (2)
<223> X is Trp

<220>
<221> VARIANT
<222> (3)
<223> X is Val, Ile, Met, Tyr, Phe, Pro or Asp

<220>
<221> VARIANT
<222> (5)
<223> X is Asn, Glu, Asp or Met

<220>
<221> VARIANT
<222> (6)
<223> X is Leu, Phe, Tyr, Trp, Val, Met, Ile, or Asn

<220>
<221> VARIANT
<222> (7)
<223> X is Phe, Leu, Asp, Glu, Ala, Ile, Lys, Asn, Ser,
Val, Trp, Tyr, Gly, or Thr

<220>
<221> VARIANT
<222> (8)
<223> X is Lys, Phe, Asp, Gly, Leu, Asn, Trp, Ala, Gln,
or Thr

<220>
<221> VARIANT
<222> (9)
<223> X is Asn, Pro, Phe, Gly, Asp, Ala, Ser, Glu, Gln,
Trp, His, Arg, Met, Val, or Leu

<220>
<221> VARIANT
<222> (10)

<223> X is Gln, Lys, Leu or Gly

<220>
<221> VARIANT
<222> (11)
<223> X is Trp, Tyr or Ala

<220>
<221> VARIANT
<222> (12)
<223> X is Phe, Thr, Met, Ser, Ala, Asn, Val, His, Ile,
Pro, Trp, Tyr, Gly, Leu or Glu

<220>
<221> VARIANT
<222> (14)
<223> X is Asn, Asp, Glu, Pro, Gln, Ser, Phe, or Val

<220>
<221> VARIANT
<222> (15)
<223> X is Val, Leu, Ile, Pro, Ala, Gln, Ser, Met, Glu,
Thr, Lys, Trp or Arg

<220>
<221> VARIANT
<222> (16)
<223> X is Leu, Met, Val, Tyr, Ala, Ile, Trp, His, Pro,
Gln, Glu, Phe, Lys, Arg or Ser

<400> 111
Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa
1 5 10 15

<210> 112
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 112
Asp Trp Val Cys Glu Trp Leu Lys Met Gln Trp Ala Cys Asn Ile Leu
1 5 10 15

<210> 113
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 113
Asp Trp Val Cys Glu Tyr Val Lys Ser Gln Trp Ser Cys Asn Pro Leu
1 5 10 15

<210> 114
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 114
Asp Trp Val Cys Glu Phe Ser Lys Val Gln Trp Tyr Cys Asn Pro Leu
1 5 10 15

<210> 115
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 115
Asp Trp Val Cys Glu Trp Phe Lys Pro Gln Trp Ile Cys Asn Leu Leu
1 5 10 15

<210> 116
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 116
Asp Trp Val Cys Glu Ile Val Lys Asn Gln Trp His Cys Asn Val Leu
1 5 10 15

<210> 117
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 117
Asp Trp Val Cys Glu Trp Gly Lys Asn Gln Trp Thr Cys Asn Pro Leu
1 5 10 15

<210> 118
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 118
Asp Trp Val Cys Glu Phe Glu Lys Gly Gln Trp Thr Cys Asn Val Leu
1 5 10 15

<210> 119
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 119
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asn Val Trp

1 5 10 15

<210> 120
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 120
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Val His
1 5 10 15

<210> 121
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 121
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Ile Arg
1 5 10 15

<210> 122
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 122
Asp Trp Val Cys Glu Trp Leu Lys Met Gln Trp Ala Cys Asn Ile Leu
1 5 10 15

<210> 123
<211> 16
<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 123
Asp Trp Val Cys Glu Phe Ile Lys Asp Gln Trp Tyr Cys Asp Leu Ala
1 5 10 15

<210> 124
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 124
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Val Val
1 5 10 15

<210> 125
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 125
Asp Trp Val Cys Glu Trp Leu Lys Met Gln Trp Ala Cys Asn Val Leu
1 5 10 15

<210> 126
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 126
Asp Trp Val Cys Glu Trp Leu Lys Asn Gln Trp Trp Cys Asn Val Leu
1 5 10 15

<210> 127
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 127
Asp Trp Val Cys Glu Leu Leu Lys Asn Gln Trp Phe Cys Asn Val Leu
1 5 10 15

<210> 128
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 128
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asn Val Leu
1 5 10 15

<210> 129
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 129
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Val Met
1 5 10 15

<210> 130

<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 130
Asp Trp Val Cys Glu Trp Phe Lys Ala Gln Trp Phe Cys Asn Met Leu
1 5 10 15

<210> 131
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 131
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Gln Leu
1 5 10 15

<210> 132
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 132
Asp Trp Met Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Val Gln
1 5 10 15

<210> 133
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic

16-mer microprotein analogues

<400> 133
Asp Trp Val Cys Glu Phe Asp Lys Gly Gln Trp Asn Cys Asn Ile Leu
1 5 10 15

<210> 134
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 134
Asp Trp Ile Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Ala Trp
1 5 10 15

<210> 135
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 135
Asp Trp Val Cys Glu Phe Asp Lys Leu Gln Trp Val Cys Asn Val Leu
1 5 10 15

<210> 136
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 136
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Gln Met
1 5 10 15

<210> 137
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 137
Asp Trp Val Cys Glu Phe Phe Lys Ser Gln Trp Tyr Cys Asn Ile Leu
1 5 10 15

<210> 138
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 138
Asp Trp Val Cys Glu Trp Leu Lys Met Gln Trp Ala Cys Asn Met Leu
1 5 10 15

<210> 139
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 139
Asp Trp Val Cys Glu Tyr Phe Lys Asn Gln Trp Leu Cys Asn Ile Leu
1 5 10 15

<210> 140
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 140
Asp Trp Val Cys Glu Trp Leu Lys Met Gln Trp Ala Cys Asn Ile Leu
1 5 10 15

<210> 141
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 141
Asp Trp Val Cys Glu Trp Leu Lys Met Gln Trp Phe Cys Asn Ala Leu
1 5 10 15

<210> 142
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 142
Asp Trp Val Cys Glu Trp Leu Lys Met Gln Trp Ala Cys Asn Val Leu
1 5 10 15

<210> 143
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 143
Asp Trp Val Cys Glu Trp Leu Lys Met Gln Trp Ala Cys Asn Met Leu

1 5 10 15

<210> 144
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 144
Asp Trp Val Cys Glu Trp Leu Lys Pro Gln Trp Tyr Cys Asn Ser Leu
1 5 10 15

<210> 145
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 145
Asp Trp Val Cys Asn Leu Phe Lys Asn Gln Trp Phe Cys Asp Leu Ser
1 5 10 15

<210> 146
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 146
Asp Trp Val Cys Glu Trp Leu Lys Ser Gln Trp Phe Cys Asn Ser Leu
1 5 10 15

<210> 147
<211> 16
<212> PRT

<400> 150
Asp Trp Val Cys Glu Phe Phe Lys Asp Gln Trp Phe Cys Asn Ile Leu
1 5 10 15

<210> 151
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
16-mer microprotein analogues

<400> 151
Asp Trp Val Cys Glu Phe Leu Lys Met Gln Trp Ala Cys Asn Val Leu
1 5 10 15

A DOCPHOENIX

BACKFILE DOCUMENT INDEX SHEET

APPL PARTS

_____ IMIS ____
Internal Misc. Paper

_____ LET. ____
Misc. Incoming Letter

_____ 371P ____
PCT Papers in a 371Application

_____ A... ____
Amendment Including Elections

_____ ABST ____
Abstract

_____ ADS ____
Application Data Sheet

_____ AF/D ____
Affidavit or Exhibit Received

_____ APPENDIX ____
Appendix

_____ ARTIFACT ____
Artifact

_____ BIB ____
Bib Data Sheet

_____ CLM ____
Claim

_____ COMPUTER ____
Computer Program Listing

_____ CRFL____
All CRF Papers for Backfile

_____ DIST ____
Terminal Disclaimer Filed

_____ DRW ____
Drawings

_____ FOR ____
Foreign Reference

_____ FRPR ____
Foreign Priority Papers

_____ IDS ____
IDS Including 1449

_____ NPL ____
Non-Patent Literature

_____ OATH ____
Oath or Declaration

_____ PET. ____
Petition

_____ RETMAIL____
Mail Returned by USPS

_____ SEQLIST ____
Sequence Listing

_____ SPEC ____
Specification

_____ SPEC NO ____
Specification Not in English

_____ TRNA ____
Transmittal New Application

OUTGOING

_____ CTMS ____
Misc. Office Action

_____ 1449 ____
Signed 1449

_____ 892 ____
892

_____ ABN ____
Abandonment

_____ APDEC ____
Board of Appeals Decision

_____ APEA ____
Examiner Answer

_____ CTAV ____
Count Advisory Action

_____ CTEQ ____
Count Ex parte Quayle

_____ CTFR ____
Count Final Rejection

_____ CTNF ____
Count Non-Final

_____ CTRS ____
Count Restriction

_____ EXIN ____
Examiner Interview

_____ M903 ____
DO/EO Acceptance

_____ M905 ____
DO/EO Missing Requirement

_____ NFDR ____
Formal Drawing Required

_____ NOA ____
Notice of Allowance

_____ PETDEC____
Petition Decision

INCOMING

_____ AP.B ____
Appeal Brief

_____ C.AD ____
Change of Address

_____ N/AP ____
Notice of Appeal

_____ PA.. ____
Change in Power of Attorney

_____ REM ____
Applicant Remarks in Amendment

_____ XT/ ____
Extension of Time filed separate

Internal

_____ SRNT____
Examiner Search Notes

_____ CLMPTO ____
PTO Prepared Complete Claim Set

_____ ECBOX ____
Evidence Copy Box Identification

_____ WCLM ____
Claim Worksheet

_____ WFEE ____
Fee Worksheet

File Wrapper

_____ FWCLM ____
File Wrapper Claim

_____ IIFW ____
File Wrapper Issue Information

_____ SRFW ____
File Wrapper Search Info

REV 7/02/03